Evidence map›Paper›PMID 36276562›Full record

ArticleNorthern clinics of Istanbul2022

HPV prevention in women aged 30-65 in Istanbul: Effect of early diagnosis of cervical cancer.

Abdullah Emre Guner, Soner Sabirli, Seniz Kavak, Kemal Kural, Ates Karateke

Abstract read
In one paragraph

Article in Northern clinics of Istanbul, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Abdullah Emre GunerDepartment of Public Health, University of Health Sciences Faculty of Medicine, Istanbul, Turkiye.
Soner SabirliDepartment of Pharmacology, University of Health Sciences Faculty of Medicine, Istanbul, Turkiye.
Seniz KavakPublic Health Services, Istanbul Health Directorate, Istanbul, Turkiye.
Kemal KuralPublic Health Services, Istanbul Health Directorate, Istanbul, Turkiye.
Ates KaratekeDepartment of Obstetrics and Gynecology, Istanbul Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEarlier detection and timely interventions against cancers are well known to reduce the morbidity and mortality. Screening programs provide opportunity to detect cancers as early as precancerous stages. Cancers of cervix of uterus are one of the cancers that have widely applicable screening methods and are one of the three cancer types that have population-based screening program in Turkiye. In this article, it is aimed to evaluate cervical cancer screenings in Istanbul.

methodsThe study methodology for cervical cancer screening conducted between 2015 and 2020 in Istanbul, Turkiye's largest city, was introduced. The results obtained in the first round of screening of 723,068 women with the human papillomavirus (HPV) method as a new methodology are discussed.

resultsAs a summary of results, the HPV positivity ratio was found to be 6.5% and the positivity rate was higher in younger women. The results also show that majority of the subjects with positive result were infected with more than 1 strains of HPV. Most prevalent subtypes detected were HPV16, HPV51, HPV31, HPV52, and HPV66, respectively. Total detection rate for any of the high-risk HPV subtypes was 29.95%.

conclusionAlthough HPV-16 is the highest subtype to be infected and total percentage of infection with any high-risk strains is approximating to one-third of the total positivity, cytological results revealed only 8.1% meaningful results.

Indexed as

Cancer screeningscervical cancerhuman papillomavirus

Identifiers

PMID36276562
PMCPMC9514075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.